Midwest Financial Partners Investments Inc. Buys Shares of 9,116 Boston Scientific Corporation $BSX

Midwest Financial Partners Investments Inc. bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 9,116 shares of the medical equipment provider’s stock, valued at approximately $869,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Signature Estate & Investment Advisors LLC raised its stake in Boston Scientific by 14.4% during the 4th quarter. Signature Estate & Investment Advisors LLC now owns 79,989 shares of the medical equipment provider’s stock valued at $7,627,000 after buying an additional 10,071 shares during the last quarter. Heritage Investors Management Corp raised its stake in Boston Scientific by 2.7% during the 4th quarter. Heritage Investors Management Corp now owns 178,205 shares of the medical equipment provider’s stock valued at $16,992,000 after buying an additional 4,751 shares during the last quarter. BOK Financial Private Wealth Inc. lifted its stake in shares of Boston Scientific by 6.2% in the 4th quarter. BOK Financial Private Wealth Inc. now owns 4,214 shares of the medical equipment provider’s stock worth $402,000 after purchasing an additional 246 shares during the period. Global Retirement Partners LLC lifted its stake in shares of Boston Scientific by 36.8% in the 4th quarter. Global Retirement Partners LLC now owns 62,528 shares of the medical equipment provider’s stock worth $5,962,000 after purchasing an additional 16,821 shares during the period. Finally, Twin Capital Management Inc. lifted its stake in shares of Boston Scientific by 0.9% in the 4th quarter. Twin Capital Management Inc. now owns 34,608 shares of the medical equipment provider’s stock worth $3,300,000 after purchasing an additional 307 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

NYSE BSX opened at $57.08 on Friday. The company has a market capitalization of $84.84 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50. The business’s fifty day moving average is $62.21 and its 200 day moving average is $80.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last three months. 0.34% of the stock is currently owned by company insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Insider purchases are often viewed as a sign of management confidence in the company’s outlook and can support sentiment around the stock.
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. The FRACTURE trial met all primary safety and effectiveness endpoints, which strengthens the case for a future regulatory submission and supports the company’s growth story in interventional cardiology.
• Neutral Sentiment: Baird kept an Outperform rating on Boston Scientific, though it trimmed its price target to $75 from $78. That suggests the firm still sees upside, but the lower target may temper enthusiasm somewhat.
• Negative Sentiment: Recent commentary also pointed to Boston Scientific having fallen on weak results, and the stock remains well below its longer-term moving averages. That indicates investors are still weighing execution concerns and broader pressure on the shares despite the upbeat insider and clinical developments.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent research reports. Citigroup lowered their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Wells Fargo & Company lowered their price objective on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. UBS Group lowered their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Jefferies Financial Group lowered their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Canaccord Genuity Group lowered their target price on Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $92.71.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.